Healthcare
LENZ Therapeutics, Inc.(LENZ)
Live Price
Offline$6.77
+4.15% today
1Y Change
-79.17%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $280.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -21.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LENZ Therapeutics, Inc. (LENZ) is a Healthcare stock with a market cap of $280.00M and listed on NASDAQ. The stock last traded around $6.77 and down 79.2% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -21.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -21.8%, free cash flow -16.9% with operating margin -477.5% and ROIC -32.0%. Valuation already assumes a fairly strong business story at price/sales 14.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LENZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-477.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -21.8%, with operating margin around -477.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.4% | -16.8% | -25.6% |
2026 Mar 24, 2026 | -27.5% | +0.4% | +1.3% | +10.6% |
2025 Nov 5, 2025 | +11.9% | +6.9% | +18.8% | +29.9% |
Benchmark Edge
LENZ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LENZ
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LENZ Max Drawdown
-87.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LENZ and SPY.
Company Overview
LENZ Therapeutics, Inc.
NASDAQ Global Select
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
- Leadership
- Evert Schimmelpennink
- IPO Date
- Mar 22, 2024
- Employees
- 6
- Street Address
- 445 Marine View Avenue
- Mailing
- Solana Beach, CA, 92014
- Region
- Solana Beach, CA, US
- Reporting Currency
- USD
- Investor Line
- (858) 925-7000
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 14.6
- Price/Book
- 1.0
Growth
- Revenue
- 0.0%
- EPS
- -21.8%
- Free Cash Flow
- -16.9%
Profitability
- Gross Margin
- 97.2%
- Operating Margin
- -477.5%
- Net Margin
- -430.3%
- ROE
- -37.5%
- ROIC
- -32.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 13.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.